A study to assess pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults
Latest Information Update: 23 Feb 2021
At a glance
- Drugs Lisdexamfetamine (Primary) ; Viloxazine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- Sponsors Supernus Pharmaceuticals
- 23 Feb 2021 New trial record
- 11 Feb 2021 Results published in the Journal of Clinical Psychopharmacology